CY1107136T1 - Πρωτεϊνες: με υψηλη ανοσοαντιδραστικοτητα καθως και μια μεθοδος για την παρασκευη τους - Google Patents

Πρωτεϊνες: με υψηλη ανοσοαντιδραστικοτητα καθως και μια μεθοδος για την παρασκευη τους

Info

Publication number
CY1107136T1
CY1107136T1 CY20081100043T CY081100043T CY1107136T1 CY 1107136 T1 CY1107136 T1 CY 1107136T1 CY 20081100043 T CY20081100043 T CY 20081100043T CY 081100043 T CY081100043 T CY 081100043T CY 1107136 T1 CY1107136 T1 CY 1107136T1
Authority
CY
Cyprus
Prior art keywords
monoclonal antibodies
proteins
preparation
produced
labeled
Prior art date
Application number
CY20081100043T
Other languages
Greek (el)
English (en)
Inventor
Ivan F Benes
Silke Thomsen-Bosslet
Original Assignee
Scintec Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scintec Diagnostics Gmbh filed Critical Scintec Diagnostics Gmbh
Publication of CY1107136T1 publication Critical patent/CY1107136T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20081100043T 2000-04-05 2008-01-11 Πρωτεϊνες: με υψηλη ανοσοαντιδραστικοτητα καθως και μια μεθοδος για την παρασκευη τους CY1107136T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10016877A DE10016877A1 (de) 2000-04-05 2000-04-05 (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung
EP01931566A EP1276770B1 (de) 2000-04-05 2001-04-04 Proteine mit hoher immunreaktivität sowie ein verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
CY1107136T1 true CY1107136T1 (el) 2012-10-24

Family

ID=7637638

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100043T CY1107136T1 (el) 2000-04-05 2008-01-11 Πρωτεϊνες: με υψηλη ανοσοαντιδραστικοτητα καθως και μια μεθοδος για την παρασκευη τους

Country Status (10)

Country Link
US (3) US7264805B2 (enExample)
EP (1) EP1276770B1 (enExample)
JP (1) JP4880854B2 (enExample)
AT (1) ATE376000T1 (enExample)
CY (1) CY1107136T1 (enExample)
DE (2) DE10016877A1 (enExample)
DK (1) DK1276770T3 (enExample)
ES (1) ES2295160T3 (enExample)
PT (1) PT1276770E (enExample)
WO (1) WO2001077179A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10016877A1 (de) * 2000-04-05 2001-10-18 Scintec Diagnostics Gmbh Zug (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung
RU2016134843A (ru) 2009-04-30 2018-12-11 Тел Хашомер Медикал Рисерч Инфрастракче Энд Сервисиз Лтд. Антитела к ceacam1 и способы их использования
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
KR102452349B1 (ko) 2014-04-27 2022-10-11 페임웨이브 리미티드 Ceacam1에 대한 인간화 항체
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5452986A (en) * 1985-02-28 1986-09-24 Verax Corp. Fluidized bioreactor and cell cultivation process
US5164175A (en) * 1986-12-10 1992-11-17 Hoechst Aktiengesellschaft Diagnostic aid containing an organ-specific substance labeled with technetium-99m
US4939087A (en) * 1987-05-12 1990-07-03 Washington State University Research Foundation, Inc. Method for continuous centrifugal bioprocessing
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
DE4125625C2 (de) * 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
AU667530B2 (en) * 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
SE9500148D0 (sv) 1995-01-18 1995-01-18 Bioinvent Internatioal Ab Antibodies for use in cancer therapy and diagnosis
EP0727480A3 (de) 1995-02-16 2000-04-12 Forschungszentrum Jülich Gmbh Verfahren zur Bestimmung von Pharmakokinetik bzw. Toxikokinetik von Testsubstanzen mit Hilfe von in-vitro-Zellkultursystemen und dafür geeignete Vorrichtungen
DE19521388C2 (de) 1995-06-13 1997-05-22 Immuno Gmbh Technik zur Bestimmung einer spezifisch-bindefähigen Substanz
DE19621388A1 (de) 1996-05-28 1997-12-11 Torsten Urban Das Tapeten- bzw. Rauhfaserset
DE19744531A1 (de) 1997-10-09 1999-05-27 Klaus Dr Rer Nat Bosslet Bindemoleküle gegen Rezeptor-Ligand-Komplexe
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
DE10016877A1 (de) * 2000-04-05 2001-10-18 Scintec Diagnostics Gmbh Zug (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
ATE376000T1 (de) 2007-11-15
DE10016877A1 (de) 2001-10-18
JP4880854B2 (ja) 2012-02-22
EP1276770B1 (de) 2007-10-17
US20030171548A1 (en) 2003-09-11
WO2001077179A1 (de) 2001-10-18
DK1276770T3 (da) 2008-02-18
EP1276770A1 (de) 2003-01-22
JP2003530126A (ja) 2003-10-14
US7264805B2 (en) 2007-09-04
US9005574B2 (en) 2015-04-14
US20080075659A1 (en) 2008-03-27
US20110008249A1 (en) 2011-01-13
PT1276770E (pt) 2008-01-24
DE50113151D1 (de) 2007-11-29
ES2295160T3 (es) 2008-04-16
US7820410B2 (en) 2010-10-26

Similar Documents

Publication Publication Date Title
Kastan et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells
EA200001169A1 (ru) Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза
NO20012223L (no) Nukleotid- og proteinsekvenser for NOGO-genene og fremgangsmåter basert derpå
DE60126104D1 (de) Ernährungszusammensetzung und verfahren zur verbesserung der absetzung von proteinen
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
CY1107136T1 (el) Πρωτεϊνες: με υψηλη ανοσοαντιδραστικοτητα καθως και μια μεθοδος για την παρασκευη τους
ES2068907T3 (es) Secuencias de nucleotidos que codifican una proteina con actividad ureasica.
LU91759I2 (fr) Denosumab et ses dérivés pharmaceutique acceptables (PROLIA®)
ATE239797T1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ATE247985T1 (de) Einführung einer thiol-gruppe in proteine für die radioimmundetektion und radioimmuntherapie auf der basis von radionukliden
ZA956254B (en) Peptides
IE893347L (en) Antibody and dna sequence encoding it
MXPA02008239A (es) Gen humano de la esquizofrenia.
ATE417930T1 (de) Proteinkinase npk-110
UA89759C2 (ru) Специфический связующий элемент, радиоактивно меченный 131и, который связывает человеческий ed-в фибронектина
ATE234858T1 (de) Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen
Spiegelberg et al. Human myeloma IgA half-molecules.
DK107787A (da) Fremgangsmaade og praeparat til behandling af cancer og ikke-maligne tumorer
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
ATE230027T1 (de) Menschliche dnase i varianten
ATE278011T1 (de) Human dnase ii
NO921219D0 (no) Somatostatin reseptor
UY27298A1 (es) Anticuerpos específicos de cd44v6
UA38678A (uk) Засіб для підвищення імунобіологічної реактивності та метаболізму організму тварин